Eli Lilly on Tuesday said its highly popular drug used for weight loss and diabetes showed promise as a treatment for fatty liver disease in a midstage trial. The initial study results add to a long list of potential health benefits of the treatment, known as tirzepatide, besides helping patients shed significant pounds and regulate blood sugar under the drug’s brand names, Zepbound and Mounjaro, respectively. Those additional benefits could potentially expand the limited insurance coverage f...